GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated.

ABSTRACT:

Background

Incretin therapies appear to provide cardioprotection and improve cardiovascular outcomes in patients with diabetes, but the mechanism of this effect remains elusive. We have previously shown that glucagon-like peptide (GLP)-1 is a coronary vasodilator and we sought to investigate if this is an adenosine-mediated effect.

Methods

We recruited 41 patients having percutaneous coronary intervention (PCI) for stable angina and allocated them into four groups administering a specific study-related infusion following successful PCI: GLP-1 infusion (Group G) (n = 10); Placebo, normal saline infusion (Group P) (n = 11); GLP-1 + Theophylline infusion (Group GT) (n = 10); and Theophylline infusion (Group T) (n = 10). A pressure wire assessment of coronary distal pressure and

SUBMITTER: Aetesam-Ur-Rahman M 

PROVIDER: S-EPMC8088691 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature